118 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
11 Mar 24
Other Events
4:09pm
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s … Ataxia
Study will inform on long-term safety profile and tissue frataxin levels
OLE initiated with 25 mg daily subcutaneous injections
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
11 Mar 19
Results of Operations and Financial Condition
4:12pm
Suspends IND filing plans forZGN-1258 based on nonclinical finding in long-term toxicology studies
Expanded executive team with highly experienced … - andsix-month long-term rodent toxicology studies. Nonclinical data showed degeneration and other anomalies in rat muscle tissue to different degrees
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
for 14 days. We are also very excited to now be able to initiate long-term dosing in the OLE trial in patients who participated in our Phase 1 or Phase 2 … studies. The ability to follow patients in a long-term study that will assess increases in frataxin over months is very important to moving
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
and assess safety to inform long-term dose and dose regimen Treatment Schedule 28-day Treatment Period 16 17 18 19 15 20 21 22 23 24 25 26 27 28 2 3 4 5 … and tolerability Evaluate long-term PK Evaluate tissue frataxin concentrations Evaluate lipid profiles and gene expression data Dosing: 25 mg daily
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
in the fourth quarter of the year which will inform on the long-term safety and tissue frataxin levels of nomlabofusp,” said Carole Ben-Maimon, MD … pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Dose escalation
8-K
EX-99.1
f6ruulouc0wtfngnhg
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
8-K
EX-99.1
bt0th
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
ack00y2 vtn5j1ps
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-99.2
sz6uqz
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.3
oy8zfk7
11 Mar 24
Other Events
4:09pm
8-K
EX-99.1
uo6b9zn
9 May 19
Zafgen Reports First Quarter 2019 Operating and Financial Results
4:26pm
8-K
EX-99.1
p7kdcw
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
10-K/A
ys54f1tufsq0ufge1or
29 Apr 16
Annual report (amended)
12:00am
8-K
EX-99.1
kj00jxx6u2vh90wyb
7 Aug 18
Zafgen Reports Second Quarter 2018 Operating and Financial Results
4:21pm
8-K
EX-99.1
se8m6i9
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.2
7ij6jjkt
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
8-K
EX-99.3
py7uk mn30l6cyxg2
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
116v0nu
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
8-K
EX-99.2
p3n3di0p
11 Mar 24
Other Events
4:09pm